These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27896589)

  • 1. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer.
    Cheng X; Liu Q; Li H; Kang C; Liu Y; Guo T; Shang K; Yan C; Cheng G; Lee RJ
    Pharm Res; 2017 Feb; 34(2):310-320. PubMed ID: 27896589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T7 Peptide-Conjugated Lipid Nanoparticles for Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical Carcinomas.
    Cheng X; Yu D; Cheng G; Yung BC; Liu Y; Li H; Kang C; Fang X; Tian S; Zhou X; Liu Q; Lee RJ
    Mol Pharm; 2018 Oct; 15(10):4722-4732. PubMed ID: 30138565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of G3139 lipid nanoparticles (LNPs).
    Pan X; Chen L; Liu S; Yang X; Gao JX; Lee RJ
    Mol Pharm; 2009; 6(1):211-20. PubMed ID: 19072654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Polyethylenimine-Containing and Transferrin-Conjugated Lipid Nanoparticle System for Antisense Oligonucleotide Delivery to AML.
    Yuan Y; Zhang L; Cao H; Yang Y; Zheng Y; Yang XJ
    Biomed Res Int; 2016; 2016():1287128. PubMed ID: 27034925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model.
    Zhang X; Koh CG; Yu B; Liu S; Piao L; Marcucci G; Lee RJ; Lee LJ
    Pharm Res; 2009 Jun; 26(6):1516-24. PubMed ID: 19291371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.
    Yang X; Koh CG; Liu S; Pan X; Santhanam R; Yu B; Peng Y; Pang J; Golan S; Talmon Y; Jin Y; Muthusamy N; Byrd JC; Chan KK; Lee LJ; Marcucci G; Lee RJ
    Mol Pharm; 2009; 6(1):221-30. PubMed ID: 19183107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo.
    Ma Y; Zhao W; Li Y; Pan Y; Wang S; Zhu Y; Kong L; Guan Z; Wang J; Zhang L; Yang Z
    Biomaterials; 2019 Mar; 197():182-193. PubMed ID: 30660994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
    Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
    Spugnini EP; Biroccio A; De Mori R; Scarsella M; D'Angelo C; Baldi A; Leonetti C
    J Transl Med; 2011 Jul; 9():125. PubMed ID: 21798045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE
    J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
    Hu Y; Bebb G; Tan S; Ng R; Yan H; Sartor JR; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Nov; 10(22):7662-70. PubMed ID: 15569999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R; Carbone R; Reiss M; Lacy J
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
    Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
    Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes.
    Chiu SJ; Liu S; Perrotti D; Marcucci G; Lee RJ
    J Control Release; 2006 May; 112(2):199-207. PubMed ID: 16564596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient delivery of the Bcl-2 antisense oligonucleotide G3139 via nucleus-targeted aCD33-NKSN nanoparticles.
    Yan C; Gu J; Zhang Y; Ma K; Lee RJ
    Int J Pharm; 2022 Sep; 625():122074. PubMed ID: 35932928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
    Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
    Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
    Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
    Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific lipoplex-mediated antisense against Bcl-2 in breast cancer cells: a comparison between different formulations.
    Meidan VM; Glezer J; Salomon S; Sidi Y; Barenholz Y; Cohen JS; Lilling G
    J Liposome Res; 2006; 16(1):27-43. PubMed ID: 16556548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.